BofA/Merrill Lynch Downgrades Hospira (HSP) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hospira, Inc. (HSP) Tops Q4 EPS by 1c; Guides FY13 EPS Below the Street
February 13, 2013 7:37 AM ESTHospira, Inc. (NYSE: HSP) reported Q4 EPS of $0.55, $0.01 better than the analyst estimate of $0.54. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.
Hospira, Inc. sees FY2013 EPS of $2.05-2.20, versus the consensus of $2.31. Sees 2013 sales growth of... More
